ClinicalTrials.gg
Active, not recruitingNCT00044304Updated Nov 12, 2026Results posted

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

A Phase 2 interventional study of Imatinib Mesylate and Ruxolitinib in Eosinophilic Myeloid Neoplasm and Hypereosinophilic Syndrome, sponsored by National Institutes of Health Clinical Center (CC). Active, not recruiting at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Institutes of Health Clinical Center (CC) · Phase 2, Interventional, and Treatment

How we know

Updated Nov 12, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Hypereosinophilic Syndrome with a site in United States — 3 open to participants now, 8 under way, 3 of them phase 3. Hypereosinophilic Syndrome · United States.

Enrollment
10th of 21
70 · median 68
Started
2002
the only one that year
Phase 2
8 of 23
1 open now
Registered
3rd of 23
by date
Lead sponsor
1 of 23
National Institutes of Health Clinical Center (CC)

Among the 23 studies in Hypereosinophilic Syndrome with a site in United States, this one is the 10th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2002, is one of 8 in phase 2, and was the 3rd registered.

Hypereosinophilic Syndrome

40 studies on the registry are indexed under Hypereosinophilic Syndrome; 8 are open to participants now.

Browse Hypereosinophilic Syndrome studies →

Open to participants now

3 of the 23 studies in Hypereosinophilic Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Hypereosinophilic Syndrome studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hypereosinophilic Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of the tyrosine kinase inhibitors, imatinib mesylate and ruxolitinib in reducing peripheral blood eosinophilia in patients with myeloid and/or steroid-refractory hypereosinophilic syndrome (HES). Patients with HES who meet a set of criteria designed to select patients with the myeloid form of the disease, as well as patients without myeloid disease who are refractory to steroid therapy for HES, will be eligible. Imatinib mesylate will be initiated at a dose of 400 mg daily, the FDA-approved dose for the treatment of chronic myelogenous leukemia (CML), in participants with a known imatinib-sensitive mutation and in participants with myeloid features without a JAK mutation. If patients fail imatinib or are steroid-resistant and do not have myeloid features, ruxolitinib therapy will be initiated at a dose of 15 mg twice daily. Patients who demonstrate a clinical and hematologic response at 1 (imatinib arm) or 3 (ruxolitinib arm) months will be eligible to continue therapy. In patients who demonstrate a complete clinical and hematologic response to imatinib therapy (including those who received imatinib prior to enrollment), imatinib may be discontinued. Patients in complete remission for ≥5 years following imatinib are considered cured and will be taken off protocol. Patients receiving ruxolitinib who demonstrate drug-related toxicity and/or a sustained clinical response to ruxolitinib for >2 years may undergo dose de-escalation.

Read the detailed description

This study will evaluate the safety and effectiveness of imatinib mesylate and ruxolitinib in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils in the blood and body tissues, which can cause damage to these tissues. Although HES can involve any tissues, the heart, nerves, and skin are most often affected. Several drugs, including steroids, interferon, and hydroxyurea can lower eosinophil counts; however, these drugs have drawbacks in that they do not work in all patients with HES, or they may work only temporarily, or patients may develop side effects that require stopping the drugs. At the time of study initiation, imatinib mesylate was a new drug approved to treat gastrointestinal tumors and chronic myelogenous leukemia. Some data suggested that imatinib mesylate might be useful in treating a subgroup of patients with HES. The study was subsequently amended to assess long-term response to imatinib and cure in patients with HES. An additional arm was later added to assess the safety and efficacy of ruxolitinib for the treatment of steroid-refractory HES.

Patients with HES who are two (2) years of age and older may be eligible for the imatinib arm of the study. Patients with HES who are 18 years or older may be eligible for the ruxolitinib arm of the study. Candidates will be screened with a medical history, physical examination, blood tests, electrocardiogram (EKG), echocardiogram (ultrasound examination of the heart), pulmonary (lung) function tests, eye exam and a bone marrow examination to determine if they fall into the subgroup of patients likely to respond to these therapies. For the bone marrow procedure, an area of skin and bone is numbed and a very sharp needle is inserted into the bone to draw out a sample of bone marrow for evaluation under the microscope.

Patients enrolled in the imatinib arm of the study will take imatinib mesylate daily. Patients enrolled on the ruxolitinib arm of the study will take ruxolitinib twice daily. Any other drugs they may be taking for HES, as well as other drugs they are taking that may interact with the study treatment, will be tapered and stopped. If it is not possible to stop taking certain drugs for other conditions, their dosages may be adjusted. Patients will be monitored weekly with laboratory testing during the first month of treatment and whenever neutrophil counts drop below 1500/mm\^3 or platelets fall below 100,000/mm\^3. If blood counts remain high enough, monitoring will be reduced to every 2 weeks for three (3) months and once a month after that. Patients receiving imatinib will have a clinic visit at NIH one (1) month after beginning the drug for a clinical and laboratory evaluation, including a repeat bone marrow examination. Patients receiving ruxolitinib will have a clinic visit at NIH 1 month after beginning the drug for a clinical and laboratory evaluation, and at 3 months for repeat evaluation, including a repeat bone marrow examination. Patients receiving imatinib whose eosinophil counts are not lowered after 4 weeks of treatment will leave the study. Those who respond to therapy will return to NIH every 3 months for a history and physical examination, laboratory tests, EKG, echocardiogram, and pulmonary function testing to determine how treatment is affecting disease progression. In some participants with stable disease where an optimal dose of imatinib mesylate has been identified, visits may be extended to every six months. Patients who achieve clinical, hematologic and molecular remission for > 2 years may undergo treatment interruption to assess for durable cure. Patients receiving ruxolitinib will undergo clinical assessments at 1 and 3 months, with repeat bone marrow examination after a minimum of 2 months of therapy. Clinical responders will continue on study with assessment every 3 months for at least one year, after which the interval between visits may be extended. In addition to the clinical assessments, the following procedures will be done solely for research purposes:

  • Blood tests to determine the effects of the study drug on immune cells, including eosinophils.
  • Leukapheresis to study the effects of imatinib mesylate on eosinophils: For this procedure, whole blood is collected through a needle in an arm vein, similar to donating blood. The blood circulates through a machine that separates it into its components, and the white cells are removed. The rest of the blood is returned to the body, either through the same needle or through another needle in the other arm.
  • Bone marrow examinations will be done during the screening tests and again 1-3 months after starting treatment, depending on the study drug, to look at newly developing cells in the bone marrow.
  • Genetic testing to determine how the study is able to lower eosinophil counts in patients with HES.
03

Conditions studied

  • Eosinophilic Myeloid Neoplasm
  • Hypereosinophilic Syndrome

Keywords

  • Janus Kinase
  • Imatinib
  • Ruxolitinib
  • Myeloid Neoplasm
  • Platelet-Derived Growth Factor Receptor Alpha
  • Hypereosinophilic Syndrome
  • HES
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Male or female, at least 2 years of age for imatinib therapy and >=18 years of age for ruxolitinib therapy.
  2. Documented diagnosis of HES: eosinophilia >1,500/mm\^3 on two occasions, no secondary etiology for the eosinophilia despite careful clinical evaluation, and evidence of end organ damage (histologic evidence of tissue infiltration by eosinophils and/or objective evidence of clinical pathology in any organ system that is temporally associated with eosinophilia and not clearly attributable to another cause).
  3. All participants must fit one of the following four categories:

    1. Myeloid neoplasm associated with a PDGFRA or PDGFRB rearrangement.
    2. Myeloid neoplasm associated with rearrangement or mutation involving the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway.
    3. Presence of >=4 of the following laboratory criteria suggestive of a myeloid disorder:

      • Dysplastic eosinophils on peripheral smear
      • Serum B12 level >= 1000 pg/mL.
      • Serum tryptase level >= 12.
      • Anemia and/or thrombocytopenia.
      • Bone marrow cellularity > 80% with left shift in maturation.
      • Dysplastic (spindle-shaped) mast cells on bone marrow .
      • Evidence of fibrosis on bone marrow biopsy.
      • Dysplastic megakaryocytes on bone marrow biopsy.
    4. to or intolerant of without evidence of a myeloid disorder.
  4. Negative serum beta-human chorionic gonadotropin 24 hours prior to drug administration for women of to exclude early pregnancy.
  5. Agrees to practice abstinence or effective during administration of imatinib mesylate or ruxolitinib and for 6 months after discontinuation of the drug. Women of childbearing potential who are using hormonal contraceptives and taking ruxolitinib will also be required to use a barrier method.**
  6. Participation in protocol 94-I-0079 (Activation and function of eosinophils in conditions with blood or tissue eosinophilia).

NOTE: Participants who meet inclusion criteria but are already receiving imatinib, may be enrolled in the dose de-escalation portion of the study at the investigator's discretion. Patients who meet inclusion criteria but are already receiving ruxolitinib may be enrolled at the investigator's discretion if baseline data are available and they have received ruxolitinib at the dose specified in the protocol for less than 2 months (primary endpoint).

**Effective contraception includes the use of hormonal (birth control pills, for example) and/or barrier (condoms and diaphragms, for example) methods by participants and/or their partners to prevent pregnancy in women of childbearing potential. For women of childbearing potential who use hormonal methods as their primary means of contraception and will be receiving treatment with ruxolitinib, barrier methods will also be required due to possible interference of ruxolitinib with hormonal contraceptives.

Although a private physician is not required for inclusion in the study, it is strongly recommended that all participants have a physician outside the NIH for routine medical care and emergencies.

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Pregnant or nursing women.*
  2. D816V KIT-positive systemic mastocytosis
  3. Uncontrolled infection (absolute lymphocyte count \<200/mm\^3 and/or HIV RNA level >500 copies/ml)
  4. (ANC) \<1000/mm\^3 or count \<10,000/mm\^3 or \<50,000/m\^3 with clinical evidence of bleeding.
  5. Elevated transaminases (>5 times the ) or elevated (>3 times the upper limit of normal).
  6. Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study.

An individual who meets any of the following criteria will be excluded from participation in the ruxolitinib treatment arm of this study:

  1. Evidence of B-cell clonality by polymerase chain reaction (PCR) or flow cytometry.
  2. Active tuberculosis, or acute or chronic active infection with or C*.
  3. Treatment with fluconazole >200 mg daily.

    • Participants with active tuberculosis will be excluded. The most current Infectious Diseases Society of America guidelines will be followed regarding isoniazid therapy for latent tuberculosis. Participants who refuse recommended prophylactic therapy for tuberculosis will be counseled regarding the risks of reactivation of tuberculosis during ruxolitinib therapy but will not be systematically excluded.
    • Molecular and serologic tests for hepatitis B and serology for will be performed regardless of vaccination history. Participants with evidence of active or chronic infection with hepatitis B or positive hepatitis C serology will be excluded from participation in the ruxolitinib arm of the protocol. Specifically, a positive hepatitis B serology indicative of previous immunization (i.e., hepatitis B anti-surface antibody-positive and hepatitis B anti-core antibody-negative) or a fully resolved acute hepatitis B infection is not an exclusion criterion. Patients with an indolent chronic hepatitis B infection (normal (ALT)), aspartate aminotransferase (AST), and albumin, and no radiographic or evidence of cirrhosis) will be evaluated by an NIH hepatologist and may be eligible. Patients who choose to remain on study with evidence of prior hepatitis B infection will be counseled regarding the risks of reactivation prior to initiation of ruxolitinib therapy.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Drug therapy 1a: imatinib mesylate in participants with FIP1L1::PDGFRA or PDGFRB translocations

    Children age two years and above and adults with steroid-refractory hypereosinophilic syndrome (HES) and FIP1L1::PDGFRA or translocations involving PDGFRB received imatinib mesylate 400 mg oral daily for three months with option to continue treatment for up to twenty years. Imatinib interruption was attempted after a minimum of two years of sustained hematologic and, if appropriate, molecular response.

    Drug: Imatinib Mesylate

  • Experimental
    Drug therapy 1b: imatinib mesylate in participants with myeloid neoplasm

    Children age two years and above and adults with steroid-refractory hypereosinophilic syndrome (HES) and features suggestive of a myeloid neoplasm without FIP1L1::PDGFRA or a translocation involving PDGFRB, received imatinib mesylate 400 mg oral daily for three months with option to continue treatment for up to twenty years. Imatinib interruption was attempted after a minimum of two years of sustained hematologic response. If participants failed imatinib, ruxolitinib therapy could be initiated at 15 mg oral twice daily.

    Drug: Imatinib Mesylate · Drug: Ruxolitinib

  • Experimental
    Drug therapy 1c: imatinib mesylate in participants with non-myeloid neoplasm

    Children age two years and above and adults with steroid-refractory hypereosinophilic syndrome (HES) and no features suggestive of a myeloid neoplasm received imatinib mesylate 400 mg oral daily for three months with option to continue treatment for up to twenty years. Imatinib interruption was attempted after 20 years of sustained hematologic response. If participants failed imatinib, ruxolitinib therapy could be initiated at 15 mg oral twice daily.

    Drug: Imatinib Mesylate · Drug: Ruxolitinib

  • Experimental
    Drug therapy 2: Ruxolitinib

    Adults with steroid-refractory FIP1L1::PDGFRA-negative, PDGFRB translocation negative, BCR::ABL-negative hypereosinophilic syndrome (HES) without myeloid features, or with a known molecular abnormality involving the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway or with imatinib-resistant HES with myeloid features received ruxolitinib 15 mg orally twice daily for up to eight years.

    Drug: Imatinib Mesylate

Interventions

  • DrugImatinibStudies of ImatinibImatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Initial dosing regimen is 400 mg oral once daily in adults and 260 mg/m\^2/day in children with food and a glass of water

    Also known as: Gleevec

  • Initially dosing regimen is 15 mg orally twice daily

    Also known as: Jakafi

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Absolute Eosinophil Count Levels in the Normal Range (<860/mm^3)

    The efficacy of treatment in reducing eosinophilia was estimated after the initiation of treatment as the percentage of participants who reached an absolute eosinophil count (AEC) levels in the normal range defined AEC \<860/mm\^3 following initiation of therapy. AEC was measured at the same time of day in each participant at specified times before and after treatment.

    Time frame: One month (for imatinib) and 3 months (for ruxolitinib)

Secondary outcomes

  1. Percentage of Participants With an Absolute Eosinophil Count (AEC) Levels Below 1500/mm^3

    The efficacy of treatment in reducing eosinophilia was estimated after the initiation of treatment as the percentage of participants who achieved an absolute eosinophil count (AEC) levels below 1500/mm\^3 following initiation of therapy.

    Time frame: One month (for imatinib) and three months (for ruxolitinib) during initial analysis; 12 months for both imatinib and ruxolitinib

07

Results

Posted Nov 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneDrug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB TranslocationsDrug Therapy 1b: Imatinib Mesylate in Participants With Myeloid NeoplasmDrug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid NeoplasmDrug Therapy 2: Ruxolitinib
Started2612819
Started on ruxolitinib after one month of imatinib therapy0120
Completed2512719
Not completed1010
Withdrew: Death1000
Withdrew: Lack of efficacy0010

Outcome measures

PrimaryPercentage of Participants With an Absolute Eosinophil Count Levels in the Normal Range (<860/mm^3)

The efficacy of treatment in reducing eosinophilia was estimated after the initiation of treatment as the percentage of participants who reached an absolute eosinophil count (AEC) levels in the normal range defined AEC \<860/mm\^3 following initiation of therapy. AEC was measured at the same time of day in each participant at specified times before and after treatment.

Time frame:
One month (for imatinib) and 3 months (for ruxolitinib)
Reported as:
Number · percentage of participants
Percentage of Participants With an Absolute Eosinophil Count Levels in the Normal Range (<860/mm^3)
percentage of participantsDrug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB TranslocationsDrug Therapy 1b: Imatinib Mesylate in Participants With Myeloid NeoplasmDrug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid NeoplasmDrug Therapy 2: Ruxolitinib
Percentage of Participants With an Absolute Eosinophil Count Levels in the Normal Range (<860/mm^3)10016.672563.64
SecondaryPercentage of Participants With an Absolute Eosinophil Count (AEC) Levels Below 1500/mm^3

The efficacy of treatment in reducing eosinophilia was estimated after the initiation of treatment as the percentage of participants who achieved an absolute eosinophil count (AEC) levels below 1500/mm\^3 following initiation of therapy.

Time frame:
One month (for imatinib) and three months (for ruxolitinib) during initial analysis; 12 months for both imatinib and ruxolitinib
Reported as:
Number · percentage of participants
Percentage of Participants With an Absolute Eosinophil Count (AEC) Levels Below 1500/mm^3
percentage of participantsDrug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB TranslocationsDrug Therapy 1b: Imatinib Mesylate in Participants With Myeloid NeoplasmDrug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid NeoplasmDrug Therapy 2: Ruxolitinib
One month (imatinib) and three months (ruxolitinib)10033.3328.5786.36
Twelve months10050—83.33

Adverse events

Collected over Participants were monitored for adverse events from one month and up to 20 year depending on duration on drug; Ruxolitinib - three months to eight years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB Translocations4/26 (15.4%)9/26 (34.6%)19/26 (73.1%)
Drug Therapy 1b: Imatinib Mesylate in Participants With Myeloid Neoplasm0/12 (0%)3/12 (25%)4/12 (33.3%)
Drug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid Neoplasm0/8 (0%)0/8 (0%)3/8 (37.5%)
Drug Therapy 2: Ruxolitinib2/22 (9.1%)11/22 (50%)21/22 (95.5%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventDrug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB TranslocationsDrug Therapy 1b: Imatinib Mesylate in Participants With Myeloid NeoplasmDrug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid NeoplasmDrug Therapy 2: Ruxolitinib
SepsisInfections and infestations0/260/120/82/22
Mitral valve diseaseCardiac disorders0/261/120/81/22
Gastrointestinal haemorrhageGastrointestinal disorders1/261/120/80/22
Acute lymphocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/261/120/80/22
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/261/120/80/22
LymphopeniaBlood and lymphatic system disorders0/260/120/81/22
Cardiac failure congestiveCardiac disorders0/260/120/81/22
BlindnessEye disorders0/260/120/81/22
ColitisGastrointestinal disorders0/260/120/81/22
VomitingGastrointestinal disorders0/260/120/81/22
Most frequent other events
Showing 10 of 136
Most frequent other events
EventDrug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB TranslocationsDrug Therapy 1b: Imatinib Mesylate in Participants With Myeloid NeoplasmDrug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid NeoplasmDrug Therapy 2: Ruxolitinib
AnaemiaBlood and lymphatic system disorders3/260/120/87/22
DiarrhoeaGastrointestinal disorders4/262/122/84/22
Urinary tract infectionInfections and infestations0/260/120/85/22
ThrombocytosisBlood and lymphatic system disorders0/260/120/84/22
COVID-19Infections and infestations0/260/120/84/22
FractureInjury, poisoning and procedural complications1/260/120/84/22
Rash pruriticSkin and subcutaneous tissue disorders0/260/120/84/22
Skin lesionSkin and subcutaneous tissue disorders0/260/120/84/22
LymphopeniaBlood and lymphatic system disorders1/260/120/83/22
InfluenzaInfections and infestations0/260/120/83/22

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB TranslocationsDrug Therapy 1b: Imatinib Mesylate in Participants With Myeloid NeoplasmDrug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid NeoplasmDrug Therapy 2: RuxolitinibTotal
<=18 years12003
Between 18 and 65 years24771654
>=65 years13138
Sex: Female, Male
Sex: Female, Male(Participants)Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB TranslocationsDrug Therapy 1b: Imatinib Mesylate in Participants With Myeloid NeoplasmDrug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid NeoplasmDrug Therapy 2: RuxolitinibTotal
Female1651224
Male2563741
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB TranslocationsDrug Therapy 1b: Imatinib Mesylate in Participants With Myeloid NeoplasmDrug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid NeoplasmDrug Therapy 2: RuxolitinibTotal
Hispanic or Latino20226
Not Hispanic or Latino241151656
Unknown or Not Reported01113
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Drug Therapy 1a: Imatinib Mesylate in Participants With FIP1L1::PDGFRA or PDGFRB TranslocationsDrug Therapy 1b: Imatinib Mesylate in Participants With Myeloid NeoplasmDrug Therapy 1c: Imatinib Mesylate in Participants With Non-myeloid NeoplasmDrug Therapy 2: RuxolitinibTotal
American Indian or Alaska Native00000
Asian11002
Native Hawaiian or Other Pacific Islander00000
Black or African American731213
White15841542
More than one race20013
Unknown or Not Reported10315
08

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
09

References and documents

Publications

  • King B, Lee AI, Choi J. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. J Invest Dermatol. 2017 Apr;137(4):951-954. doi: 10.1016/j.jid.2016.10.044. Epub 2016 Nov 22. No abstract available. PubMed 27887955 ↗
  • Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015 Aug 27;126(9):1069-77. doi: 10.1182/blood-2014-11-551614. Epub 2015 May 11. PubMed 25964669 ↗
  • Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003 Jun 15;101(12):4660-6. doi: 10.1182/blood-2003-01-0006. Epub 2003 Apr 3. PubMed 12676775 ↗
  • Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004 Jan 15;103(2):473-8. doi: 10.1182/blood-2003-08-2798. Epub 2003 Sep 22. PubMed 14504092 ↗
  • Khoury P, Desmond R, Pabon A, Holland-Thomas N, Ware JM, Arthur DC, Kurlander R, Fay MP, Maric I, Klion AD. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. Allergy. 2016 Jun;71(6):803-10. doi: 10.1111/all.12843. Epub 2016 Mar 2. PubMed 26797802 ↗
  • Pongdee T, Berry A, Wetzler L, Sun X, Thumm L, Yoon P, Kuang FL, Makiya M, Constantine G, Khoury P, Rheinbay E, Lane AA, Maric I, Klion AD. False-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay. Acta Haematol. 2023;146(4):316-321. doi: 10.1159/000528046. Epub 2023 Jun 7. PubMed 37285821 ↗
  • Klion AD, Robyn J, Maric I, Fu W, Schmid L, Lemery S, Noel P, Law MA, Hartsell M, Talar-Williams C, Fay MP, Dunbar CE, Nutman TB. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood. 2007 Nov 15;110(10):3552-6. doi: 10.1182/blood-2007-07-100164. Epub 2007 Aug 20. PubMed 17709602 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As such, this trial will be registered at ClinicalTrials.gov, and results information from this trial will be submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer-reviewed journals.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be requested after publication.

Access criteria: Data from this study may be requested from other researchers at any time after the completion of the primary endpoint by contacting the PI.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2002 to primary completion in Nov 2023, 253 months.

Results were first posted in Nov 2026, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2002
First posted
Aug 26, 2002
StartActual
Sep 26, 2002
Primary completionActual
Nov 16, 2023
CompletionEst.
Mar 10, 2027
Results first posted
Nov 12, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 12, 2026
Eligibility
3 inclusion criteria edited, 1 removed; 3 exclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedMyeloid neoplasm associated with rearrangement or mutation involving the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway.
  • EditedNOTE: Participants who meet inclusion criteria but are already receiving imatinib, may be enrolled in the dose de-escalation portion of the study at the investigator 's discretion. Patients who meet inclusion criteria but are already receiving ruxolitinib may be enrolled at the investigator 's discretion if baseline data are available and they have received ruxolitinib at the dose specified in the protocol for less than 2 months (primary endpoint).
  • Edited**Effective contraception includes the use of hormonal (birth control pills, for example) and/or barrier (condoms and diaphragms, for example) methods by participants and/or their partners to prevent pregnancy in women of childbearing potential. For women of childbearing potential who use hormonal methods as their primary means of contraception and will be receiving treatment with ruxolitinib, barrier methods will also be required due to possible interference of ruxolitinib with hormonal contraceptives.
  • Removedwith ruxolitinib, barrier methods will also be required due to possible interference of ruxolitinib with hormonal contraceptives.
Exclusion criteria
  • EditedAbsolute neutrophil count (ANC) <1000/mm\^3 or platelet count <10,000/mm\^3 or <50,000/m\^3 with clinical evidence of bleeding.
  • EditedEvidence of B-cell clonality by polymerase chain reaction (PCR) or flow cytometry.
  • AddedParticipants with active tuberculosis will be excluded. The most current Infectious Diseases Society of America guidelines will be followed regarding isoniazid therapy for latent tuberculosis. Participants who refuse recommended prophylactic therapy for tuberculosis will be counseled regarding the risks of reactivation of tuberculosis during ruxolitinib therapy but will not be systematically excluded.
  • EditedParticipants with active tuberculosis will be excluded. The most current Infectious Diseases Society of America guidelines will be followed regarding isoniazid therapy for latent tuberculosis. Participants who refuse recommended prophylactic therapy for tuberculosis will be counseled regarding the risks of reactivation of tuberculosis during ruxolitinib therapy but will not be systematically excluded. Molecular and serologic tests for hepatitis B and serology for hepatitis C will be performed regardless of vaccination history. Participants with evidence of active or chronic infection with hepatitis B or positive hepatitis C serology will be excluded from participation in the ruxolitinib arm of the protocol. Specifically, a positive hepatitis B serology indicative of previous immunization (i.e., hepatitis B anti-surface antibody-positive and hepatitis B anti-core antibody-negative) or a fully resolved acute hepatitis B infection is not an exclusion criterion. Patients with an indolent chronic hepatitis B infection (normal alanine aminotransferase [(ALT])), aspartate aminotransferase [(AST]), and albumin, and no radiographic or biopsy evidence of cirrhosis) will be evaluated by an NIH hepatologist and may be eligible. Patients who choose to remain on study with evidence of prior hepatitis B infection will be counseled regarding the risks of reactivation prior to initiation of ruxolitinib therapy.
Nov 12, 2026
Interventions
Changed Imatinib→Imatinib Mesylate. Arm changed Ruxolitinib→Drug therapy 2: Ruxolitinib. Arms added: Drug therapy 1a: imatinib mesylate in participants with FIP1L1::PDGFRA or PDGFRB translocations·Drug therapy 1b: imatinib mesylate in participants with myeloid neoplasm·Drug therapy 1c: imatinib mesylate in participants with non-myeloid neoplasm; arms removed: Imatinib
Nov 12, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore peripheral blood absolute eosinophil count.Now Percentage of Participants With an Absolute Eosinophil Count Levels in the Normal Range (<860/mm^3)Time frame: one month (for imatinib) and 3 months (for ruxolitinib). → One month (for imatinib) and 3 months (for ruxolitinib)
Nov 12, 2026
Documents
Publications
Results publication added: Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB. Elevated serum tryptase levels identify a subset of patients with a myeloproli… PubMed 12676775 ↗; 2 more
Nov 12, 2026
Secondary outcomes
1 added, 4 removed
What changed in the outcomes
  • AddedPercentage of Participants With an Absolute Eosinophil Count (AEC) Levels Below 1500/mm^3Time frame: One month (for imatinib) and three months (for ruxolitinib) during initial analysis; 12 months for both imatinib and ruxolitinib
  • Removedperipheral blood eosinophil countTime frame: 3,6,9 and 12 months
  • Removedperipheral blood eosinophil countTime frame: 1, 3, 6, 9, and 12 months
  • Removedabnormal tyrosine kinase (i.e., FIP1L1-PDGFRA, JAK2 V617F)Time frame: every 3 months for 5 years
  • Removedclinical, hematologic and molecular remissionTime frame: every 3 months for 5 years
Nov 12, 2026
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)→National Institutes of Health Clinical Center (CC)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Results posted
    Publications Results publication added: Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB. Elevated serum tryptase levels identify a subset of patients with a myeloproli… PubMed 12676775 ↗; 2 more
    Eligibility 3 inclusion criteria edited, 1 removed; 3 exclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedMyeloid neoplasm associated with rearrangement or mutation involving the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway.
    • EditedNOTE: Participants who meet inclusion criteria but are already receiving imatinib, may be enrolled in the dose de-escalation portion of the study at the investigator 's discretion. Patients who meet inclusion criteria but are already receiving ruxolitinib may be enrolled at the investigator 's discretion if baseline data are available and they have received ruxolitinib at the dose specified in the protocol for less than 2 months (primary endpoint).
    • Edited**Effective contraception includes the use of hormonal (birth control pills, for example) and/or barrier (condoms and diaphragms, for example) methods by participants and/or their partners to prevent pregnancy in women of childbearing potential. For women of childbearing potential who use hormonal methods as their primary means of contraception and will be receiving treatment with ruxolitinib, barrier methods will also be required due to possible interference of ruxolitinib with hormonal contraceptives.
    • Removedwith ruxolitinib, barrier methods will also be required due to possible interference of ruxolitinib with hormonal contraceptives.
    Exclusion criteria
    • EditedAbsolute neutrophil count (ANC) <1000/mm\^3 or platelet count <10,000/mm\^3 or <50,000/m\^3 with clinical evidence of bleeding.
    • EditedEvidence of B-cell clonality by polymerase chain reaction (PCR) or flow cytometry.
    • AddedParticipants with active tuberculosis will be excluded. The most current Infectious Diseases Society of America guidelines will be followed regarding isoniazid therapy for latent tuberculosis. Participants who refuse recommended prophylactic therapy for tuberculosis will be counseled regarding the risks of reactivation of tuberculosis during ruxolitinib therapy but will not be systematically excluded.
    • EditedParticipants with active tuberculosis will be excluded. The most current Infectious Diseases Society of America guidelines will be followed regarding isoniazid therapy for latent tuberculosis. Participants who refuse recommended prophylactic therapy for tuberculosis will be counseled regarding the risks of reactivation of tuberculosis during ruxolitinib therapy but will not be systematically excluded. Molecular and serologic tests for hepatitis B and serology for hepatitis C will be performed regardless of vaccination history. Participants with evidence of active or chronic infection with hepatitis B or positive hepatitis C serology will be excluded from participation in the ruxolitinib arm of the protocol. Specifically, a positive hepatitis B serology indicative of previous immunization (i.e., hepatitis B anti-surface antibody-positive and hepatitis B anti-core antibody-negative) or a fully resolved acute hepatitis B infection is not an exclusion criterion. Patients with an indolent chronic hepatitis B infection (normal alanine aminotransferase [(ALT])), aspartate aminotransferase [(AST]), and albumin, and no radiographic or biopsy evidence of cirrhosis) will be evaluated by an NIH hepatologist and may be eligible. Patients who choose to remain on study with evidence of prior hepatitis B infection will be counseled regarding the risks of reactivation prior to initiation of ruxolitinib therapy.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore peripheral blood absolute eosinophil count.Now Percentage of Participants With an Absolute Eosinophil Count Levels in the Normal Range (<860/mm^3)Time frame: one month (for imatinib) and 3 months (for ruxolitinib). → One month (for imatinib) and 3 months (for ruxolitinib)
    Secondary outcomes 1 added, 4 removed
    What changed in the outcomes
    • AddedPercentage of Participants With an Absolute Eosinophil Count (AEC) Levels Below 1500/mm^3Time frame: One month (for imatinib) and three months (for ruxolitinib) during initial analysis; 12 months for both imatinib and ruxolitinib
    • Removedperipheral blood eosinophil countTime frame: 3,6,9 and 12 months
    • Removedperipheral blood eosinophil countTime frame: 1, 3, 6, 9, and 12 months
    • Removedabnormal tyrosine kinase (i.e., FIP1L1-PDGFRA, JAK2 V617F)Time frame: every 3 months for 5 years
    • Removedclinical, hematologic and molecular remissionTime frame: every 3 months for 5 years
    Interventions Changed Imatinib→Imatinib Mesylate. Arm changed Ruxolitinib→Drug therapy 2: Ruxolitinib. Arms added: Drug therapy 1a: imatinib mesylate in participants with FIP1L1::PDGFRA or PDGFRB translocations·Drug therapy 1b: imatinib mesylate in participants with myeloid neoplasm·Drug therapy 1c: imatinib mesylate in participants with non-myeloid neoplasm; arms removed: Imatinib
    Sponsor National Institute of Allergy and Infectious Diseases (NIAID)→National Institutes of Health Clinical Center (CC)
    + 4 other changes: verification date, oversight details, description and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT00044304
Responsible party
Sponsor
First posted
Aug 26, 2002
Start date
Sep 26, 2002
Primary completion
Nov 16, 2023
Completion
Mar 10, 2027 (estimated)
Results posted
Nov 12, 2026
Last update
Nov 12, 2026

Study contacts

Amy D Klion, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion